|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
BRPI0906473A8
(pt)
|
2008-01-04 |
2016-02-10 |
Intellikine Inc |
Certas entidades químicas, composições e métodos
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
EP2448938B9
(en)
|
2009-06-29 |
2015-06-10 |
Incyte Corporation |
Pyrimidinones as pi3k inhibitors
|
|
EP2525790B1
(en)
|
2009-10-21 |
2020-05-27 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
WO2011050210A1
(en)
|
2009-10-21 |
2011-04-28 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
WO2011075630A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
|
|
WO2011075643A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
|
US9403769B2
(en)
|
2010-02-22 |
2016-08-02 |
Advanced Cancer Therapeutics, Llc |
Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
|
RU2569678C2
(ru)
|
2010-04-22 |
2015-11-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения циклоалкилкарбоксамидо-индольных соединений
|
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
|
WO2011161201A1
(en)
|
2010-06-22 |
2011-12-29 |
Kancera Ab |
Bisarylsulfonamides useful as kinase inhibitors in the treatment of inflammation and cancer
|
|
WO2012035171A2
(en)
|
2010-09-17 |
2012-03-22 |
Kancera Ab |
New compounds
|
|
JP5961187B2
(ja)
|
2010-12-20 |
2016-08-02 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
|
|
EP3238722B1
(en)
|
2011-01-10 |
2019-03-13 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones
|
|
GB201103762D0
(en)
|
2011-03-07 |
2011-04-20 |
Vib Vzw |
Means and methods for the treatment of neurodegenerative disorders
|
|
US9108984B2
(en)
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
|
US9492418B2
(en)
|
2011-05-10 |
2016-11-15 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Inhibitors of PFKFB3 for cancer therapy
|
|
RU2477723C2
(ru)
|
2011-06-16 |
2013-03-20 |
Общество С Ограниченной Ответственностью "Фьюжн Фарма" |
Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
|
|
GB201112145D0
(en)
|
2011-07-15 |
2011-08-31 |
Vib Vzw |
Means and methods for the treatment of pathological angiogenesis
|
|
MX389479B
(es)
|
2011-09-02 |
2025-03-20 |
Incyte Holdings Corp |
Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
|
|
ES2649116T3
(es)
|
2011-12-22 |
2018-01-10 |
Kancera Ab |
Bisarilsulfonamidas útiles en el tratamiento de inflamación y cáncer
|
|
US10000449B2
(en)
|
2011-12-22 |
2018-06-19 |
Kancera Ab |
Bisarylsulfonamides useful in the treatment of inflammation and cancer
|
|
WO2013148228A1
(en)
|
2012-03-29 |
2013-10-03 |
Advanced Cancer Therapeutics, Llc |
Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
RU2702908C2
(ru)
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
|
US8871754B2
(en)
|
2012-11-19 |
2014-10-28 |
Irm Llc |
Compounds and compositions for the treatment of parasitic diseases
|
|
LT2925757T
(lt)
|
2012-11-19 |
2017-12-27 |
Novartis Ag |
Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
|
|
ES2670550T3
(es)
|
2013-10-14 |
2018-05-30 |
Eisai R&D Management Co., Ltd. |
Derivados de quinolina selectivamente sustituidos
|
|
KR101823488B1
(ko)
|
2013-10-14 |
2018-01-30 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
선택적으로 치환된 퀴놀린 화합물
|
|
PL3925607T5
(pl)
|
2014-04-15 |
2026-06-01 |
Vertex Pharmaceuticals Incorporated |
Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
GB201407693D0
(en)
*
|
2014-05-01 |
2014-06-18 |
Univ Montfort |
Compound
|
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
|
SG10201912302VA
(en)
|
2015-02-27 |
2020-02-27 |
Incyte Corp |
Salts of pi3k inhibitor and processes for their preparation
|
|
US10881654B2
(en)
*
|
2015-04-24 |
2021-01-05 |
University Of Louisville Research Foundation, Inc. |
Selective PFKFB4 inhibitors for the treatment of cancer
|
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
|
EP3294728A1
(en)
*
|
2015-05-13 |
2018-03-21 |
Selvita S.A. |
Substituted quinoxaline derivatives
|
|
WO2016191660A1
(en)
*
|
2015-05-28 |
2016-12-01 |
University Of Louisville Research Foundation, Inc. |
Combinations of pfkfb3 inhibitors and immune checkpoint inhibitors to treat cancer
|
|
WO2017208174A2
(en)
*
|
2016-05-31 |
2017-12-07 |
The Regents Of The University Of California |
Methods of treating disease with pfkfb3 inhibitors
|
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
AU2018300150A1
(en)
|
2017-07-11 |
2020-01-30 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
US10774046B2
(en)
|
2017-10-26 |
2020-09-15 |
University Of Louisville Research Foundation, Inc. |
Inhibitors for the treatment of cancer and related methods
|
|
IL278889B2
(en)
|
2018-06-01 |
2025-11-01 |
Incyte Corp |
Dosing regimen for the treatment of pi3k related disorders
|
|
WO2020030613A1
(en)
|
2018-08-07 |
2020-02-13 |
Kemijski Institut |
Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing lactate generation by cancer cells
|
|
CN109535068B
(zh)
*
|
2018-12-26 |
2022-07-29 |
中国药科大学 |
吡啶取代查尔酮类化合物或其可药用的盐及其制备方法和用途
|
|
WO2020146612A1
(en)
|
2019-01-10 |
2020-07-16 |
Vertex Pharmaceuticals Incorporated |
Esters and carbamates as modulators of sodium channels
|
|
WO2020146682A1
(en)
|
2019-01-10 |
2020-07-16 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
PH12022551379A1
(en)
|
2019-12-06 |
2023-05-03 |
Vertex Pharma |
Substituted tetrahydrofurans as modulators of sodium channels
|
|
JP2023538612A
(ja)
|
2020-08-18 |
2023-09-08 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
糖尿病治療及びベータ細胞再生のための方法及び組成物
|
|
SI4347031T1
(sl)
|
2021-06-04 |
2026-01-30 |
Vertex Pharmaceuticals Incorporated |
N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
|
|
LU102863B1
(en)
|
2021-10-19 |
2023-04-20 |
Kemijski Inst |
Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing Reactive oxygen species (ROS) generation by cancer cells
|